OBJECTIVE: Prader-Willi syndrome (PWS) is a genetic syndrome characterized by relative hypoinsulinaemia and normal or increased insulin sensitivity despite profound obesity. We hypothesized that this increased insulin sensitivity is mediated by increased levels of total and high molecular weight adiponectin and associated with changes in levels of satiety hormones. DESIGN, PATIENTS AND MEASUREMENTS: We measured total adiponectin and its isoforms [high molecular weight (HMW), middle molecular weight (MMW) and low molecular weight (LMW) adiponectin] and satiety hormones in 14 children with PWS [median age 11.35 years, body mass index (BMI) Z-score 2.15] and 14 BMI-matched controls (median age 11.97 years, BMI Z-score 2.34). RESULTS: Despite comparable BMI Z-scores and leptin levels, the PWS children exhibited lower fasting insulin and HOMA-IR (homeostasis model assessment of insulin resistance) scores compared to obese controls. For any given BMI Z-score, the PWS children showed higher concentrations of fasting total and HMW adiponectin and higher HMW/total adiponectin ratios. The HMW/total adioponectin ratio was preserved in children with PWS at high degrees of obesity. In PWS children, fasting plasma total adiponectin, HMW adiponectin and HMW/total adiponectin ratio correlated negatively with age (P < 0.05), HOMA-IR (P < 0.01), BMI Z-score (P < 0.05), insulin (P < 0.01) and leptin (P < 0.05). In addition to higher fasting ghrelin concentrations, the PWS children showed significantly higher fasting levels of total peptide YY (PYY) and gastric inhibitory polypeptide (GIP) compared to obese controls. CONCLUSIONS: Relative to controls of similar age and BMI Z-score, the PWS children had significantly higher levels of total and HMW adiponectin, and increased ratios of HMW/total adiponectin. These findings may explain in part the heightened insulin sensitivity of PWS children relative to BMI-matched controls.
OBJECTIVE:Prader-Willi syndrome (PWS) is a genetic syndrome characterized by relative hypoinsulinaemia and normal or increased insulin sensitivity despite profound obesity. We hypothesized that this increased insulin sensitivity is mediated by increased levels of total and high molecular weight adiponectin and associated with changes in levels of satiety hormones. DESIGN, PATIENTS AND MEASUREMENTS: We measured total adiponectin and its isoforms [high molecular weight (HMW), middle molecular weight (MMW) and low molecular weight (LMW) adiponectin] and satiety hormones in 14 children with PWS [median age 11.35 years, body mass index (BMI) Z-score 2.15] and 14 BMI-matched controls (median age 11.97 years, BMI Z-score 2.34). RESULTS: Despite comparable BMI Z-scores and leptin levels, the PWSchildren exhibited lower fasting insulin and HOMA-IR (homeostasis model assessment of insulin resistance) scores compared to obese controls. For any given BMI Z-score, the PWSchildren showed higher concentrations of fasting total and HMW adiponectin and higher HMW/total adiponectin ratios. The HMW/total adioponectin ratio was preserved in children with PWS at high degrees of obesity. In PWSchildren, fasting plasma total adiponectin, HMW adiponectin and HMW/total adiponectin ratio correlated negatively with age (P < 0.05), HOMA-IR (P < 0.01), BMI Z-score (P < 0.05), insulin (P < 0.01) and leptin (P < 0.05). In addition to higher fasting ghrelin concentrations, the PWSchildren showed significantly higher fasting levels of total peptide YY (PYY) and gastric inhibitory polypeptide (GIP) compared to obese controls. CONCLUSIONS: Relative to controls of similar age and BMI Z-score, the PWSchildren had significantly higher levels of total and HMW adiponectin, and increased ratios of HMW/total adiponectin. These findings may explain in part the heightened insulin sensitivity of PWSchildren relative to BMI-matched controls.
Authors: David E Cummings; Karine Clement; Jonathan Q Purnell; Christian Vaisse; Karen E Foster; R Scott Frayo; Michael W Schwartz; Arnaud Basdevant; David S Weigle Journal: Nat Med Date: 2002-07 Impact factor: 53.440
Authors: D A M Festen; A van Toorenenbergen; H J Duivenvoorden; A C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2007-01-30 Impact factor: 5.958
Authors: A Ciresi; M C Amato; A Criscimanna; A Mattina; C Vetro; A Galluzzo; G D'Acquisto; C Giordano Journal: Eur J Endocrinol Date: 2007-03 Impact factor: 6.664
Authors: A P Goldstone; E L Thomas; A E Brynes; J D Bell; G Frost; N Saeed; J V Hajnal; J K Howard; A Holland; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Joan C Han; Michael J Muehlbauer; Huaxia N Cui; Christopher B Newgard; Andrea M Haqq Journal: J Clin Endocrinol Metab Date: 2010-04-28 Impact factor: 5.958
Authors: Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan Journal: CNS Drugs Date: 2012-04-01 Impact factor: 5.749
Authors: Krystal A Irizarry; James Bain; Merlin G Butler; Olga Ilkayeva; Michael Muehlbauer; Andrea M Haqq; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2015-04-01 Impact factor: 3.478
Authors: Andrea M Haqq; Michael J Muehlbauer; Christopher B Newgard; Steven Grambow; Michael Freemark Journal: J Clin Endocrinol Metab Date: 2010-10-20 Impact factor: 5.958
Authors: Pinar Gumus Balikcioglu; Metin Balikcioglu; Michael J Muehlbauer; Jonathan Q Purnell; David Broadhurst; Michael Freemark; Andrea M Haqq Journal: J Clin Endocrinol Metab Date: 2015-08-10 Impact factor: 5.958
Authors: Andrea M Haqq; Steven C Grambow; Michael Muehlbauer; Christopher B Newgard; Laura P Svetkey; Aaron L Carrel; Jack A Yanovski; Jonathan Q Purnell; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2008-08-15 Impact factor: 3.478